Home » Approval in Canada to Begin Two Phase II Trials of Nimotuzumab
Approval in Canada to Begin Two Phase II Trials of Nimotuzumab
YM BioSciences Inc. has received clearance from Canadian regulatory authorities to initiate two Phase II, double-blind, randomized trials for nimotuzumab, its EGFR-targeting antibody, in combination with radiation-based treatments.
TradingMarkets
TradingMarkets
Upcoming Events
-
07May
-
14May
-
30May